Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.72 |
| ▸ | EGLN2 | Q96KS0 | 14/20 | 0.59 |
| ▸ | THRA | P10827 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409409 | 0.96 | EGLN1 (0.77) | EGLN1EGLN2THRATHRB | |
| SCHEMBL523531 | 0.93 | EGLN1 (0.78) | EGLN1EGLN2 | |
| SCHEMBL523331 | 0.93 | EGLN1 (0.70) | EGLN1EGLN2THRATHRB | |
| SCHEMBL30274462 | 0.92 | EGLN1 (0.84) | EGLN1EGLN2 | |
| SCHEMBL522721 | 0.92 | EGLN1 (0.84) | EGLN1EGLN2 | |
| SCHEMBL523170 | 0.92 | EGLN1 (0.84) | EGLN1EGLN2 | |
| SCHEMBL523169 | 0.92 | EGLN1 (0.70) | EGLN1EGLN2THRATHRB | |
| SCHEMBL523054 | 0.92 | EGLN1 (0.70) | EGLN1EGLN2THRATHRB | |
| SCHEMBL4758056 | 0.90 | EGLN1 (0.68) | EGLN1EGLN2THRATHRB | |
| SCHEMBL5072579 | 0.89 | EGLN1 (0.67) | EGLN1EGLN2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| WO-2009002533-A1 | INFLAMMATORY BOWEL DISEASE THERAPIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |